Part4:ABBV-400单药,未携带BRAF V600E突变和dMMR+/MSI-Hi晚期CRC; Part5:ABBV-400单药,MET扩增,不限癌种; Part6:ABBV-400单药,MET突变,不腺癌种; Part7:ABBV-399联合贝伐珠单抗,结直肠癌CRC; Part8:ABBV-399联合贝伐珠单抗或曲氟尿苷替匹嘧啶(TA...
一项1期试验(NCT05029882)的数据显示,靶向c-Met的新型ADC药物ABBV-400在BRAF野生型、微卫星稳定型(MSS)/错配修复良好型(pMMR)晚期结直肠癌(CRC)患者中显示出初步的抗肿瘤活性,且患者耐受性良好。港安健康国际医疗介绍,ABBV-400将c-Met靶向抗体telisotuzumab与拓扑异构酶1抑制剂有效载荷相结合。c-Met的过表达在...
在2.4 mg/kg和3.0 mg/kg剂量下,ABBV-400在CRC患者中显示出良好的抗肿瘤活性,同时具有可接受的安全性和可控的副作用。 中国上市:近日,国家药品监督管理局药品审评中心(CDE)正式将艾伯维临床研发阶段的输注用无菌冻干粉Telisotuzumab Vedotin(Teliso-V)纳入突破性治疗药物品种名单,拟用于治疗在铂类药物治疗期间或治...
参考来源: https://www.onclive.com/view/telisotuzumab-adizutecan-represents-a-novel-c-met-targeting-adc-in-met-amplified-crc 编者按 如果您希望了解更多癌症等重大、复杂疾病的海外前沿研究成果、药物、疗法信息,请扫描下方二维码联...
;12.仅限扩展第 2 部分: -组织学诊断为恶性实体瘤(世界卫生组织 [WHO] 标准)。 -根据 RECIST 1.1 版,存在可测量的疾病。 -受试者患有晚期实体瘤,包括(但不限于)非小细胞肺癌(NSCLC)、头颈部鳞状细胞癌(HNSCC)、胃食管连接部腺癌(GEA)、结肠直肠癌 (CRC)和肾细胞癌(RCC),其在标...
There are no approved therapies specific for c-Met–overexpressing tumors in CRC. The antibody-drug conjugate ABBV-400 comprises c-Met–targeting antibody telisotuzumab conjugated to a novel topoisomerase 1 inhibitor payload. A phase 1 study of ABBV-400 was initiated for adults with advanced ...
Delve into Recent NCCN Guideline Updates for Hepatobiliary and CRC Management: With Alan P. Venook, MD March 9th 2025 The OncFive: Top Oncology Articles for the Week of 3/2 September 12th 2024 Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress March 8th 2025 Nivolu...
Kanwal P.S. Raghav, MD, MBBS, discusses a phase 2 study of ABBV-400 plus 5-FU, folinic acid, and bevacizumab in pretreated patients with metastatic CRC.
一项1期试验(NCT05029882)的数据显示,靶向c-Met的新型ADC药物ABBV-400在BRAF野生型、微卫星稳定型(MSS)/错配修复良好型(pMMR)晚期结直肠癌(CRC)患者中显示出初步的抗肿瘤活性,且患者耐受性良好。港安健康国际医疗介绍,ABBV-400将c-Met靶向抗体telisotuzumab与拓扑异构酶1抑制剂有效载荷相结合。c-Met的过表达在...
To extend activity of a c-Met-targeted ADC to patients with tumors expressing lower c-Met levels and to indications, such as colorectal cancer (CRC), where MMAE-based ADCs have not been effective, a novel topoisomerase-1 inhibitor linker-drug was developed. Screening over 400 linker-drugs ...